Literature DB >> 28750143

Characterization of Small-Molecule Scaffolds That Bind to the Shigella Type III Secretion System Protein IpaD.

Supratim Dey1, Asokan Anbanandam2, Ben E Mumford1, Roberto N De Guzman1.   

Abstract

Many pathogens such as Shigella and other bacteria assemble the type III secretion system (T3SS) nanoinjector to inject virulence proteins into their target cells to cause infectious diseases in humans. The rise of drug resistance among pathogens that rely on the T3SS for infectivity, plus the dearth of new antibiotics require alternative strategies in developing new antibiotics. The Shigella T3SS tip protein IpaD is an attractive target for developing anti-infectives because of its essential role in virulence and its exposure on the bacterial surface. Currently, the only known small molecules that bind to IpaD are bile salt sterols. In this study we identified four new small-molecule scaffolds that bind to IpaD, based on the methylquinoline, pyrrolidine-aniline, hydroxyindole, and morpholinoaniline scaffolds. NMR mapping revealed potential hotspots in IpaD for binding small molecules. These scaffolds can be used as building blocks in developing small-molecule inhibitors of IpaD that could lead to new anti-infectives.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  IpaD; NMR spectroscopy; small molecules; surface plasmon resonance; type III secretion system

Mesh:

Substances:

Year:  2017        PMID: 28750143      PMCID: PMC5741093          DOI: 10.1002/cmdc.201700348

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  38 in total

Review 1.  NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors.

Authors:  Bernd Meyer; Thomas Peters
Journal:  Angew Chem Int Ed Engl       Date:  2003-02-24       Impact factor: 15.336

2.  Using NMRView to visualize and analyze the NMR spectra of macromolecules.

Authors:  Bruce A Johnson
Journal:  Methods Mol Biol       Date:  2004

Review 3.  Protein delivery into eukaryotic cells by type III secretion machines.

Authors:  Jorge E Galán; Hans Wolf-Watz
Journal:  Nature       Date:  2006-11-30       Impact factor: 49.962

4.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

5.  IpaD of Shigella flexneri is independently required for regulation of Ipa protein secretion and efficient insertion of IpaB and IpaC into host membranes.

Authors:  Wendy L Picking; Hiroaki Nishioka; Patricia D Hearn; M Aaron Baxter; Amanda T Harrington; Ariel Blocker; William D Picking
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri.

Authors:  Marianela Espina; Andrew J Olive; Roma Kenjale; David S Moore; S Fernando Ausar; Robert W Kaminski; Edwin V Oaks; C Russell Middaugh; William D Picking; Wendy L Picking
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

7.  Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip.

Authors:  Kenneth F Stensrud; Philip R Adam; Cassandra D La Mar; Andrew J Olive; Gerald H Lushington; Raghavi Sudharsan; Naomi L Shelton; Richard S Givens; Wendy L Picking; William D Picking
Journal:  J Biol Chem       Date:  2008-05-01       Impact factor: 5.157

8.  Identification of the MxiH needle protein residues responsible for anchoring invasion plasmid antigen D to the type III secretion needle tip.

Authors:  Lingling Zhang; Yu Wang; Andrew J Olive; Nathan D Smith; William D Picking; Roberto N De Guzman; Wendy L Picking
Journal:  J Biol Chem       Date:  2007-09-07       Impact factor: 5.157

9.  Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton.

Authors:  Andreas K J Veenendaal; Charlotta Sundin; Ariel J Blocker
Journal:  J Bacteriol       Date:  2008-11-07       Impact factor: 3.490

10.  Self-chaperoning of the type III secretion system needle tip proteins IpaD and BipD.

Authors:  Steven Johnson; Pietro Roversi; Marianela Espina; Andrew Olive; Janet E Deane; Susan Birket; Terry Field; William D Picking; Ariel J Blocker; Edouard E Galyov; Wendy L Picking; Susan M Lea
Journal:  J Biol Chem       Date:  2006-10-31       Impact factor: 5.157

View more
  6 in total

Review 1.  The type III secretion system needle, tip, and translocon.

Authors:  Supratim Dey; Amritangshu Chakravarty; Pallavi Guha Biswas; Roberto N De Guzman
Journal:  Protein Sci       Date:  2019-08-02       Impact factor: 6.725

Review 2.  Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.

Authors:  Hiroshi Ogawara
Journal:  J Antibiot (Tokyo)       Date:  2020-07-09       Impact factor: 2.649

Review 3.  On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome.

Authors:  Bronwyn J E Lyons; Natalie C J Strynadka
Journal:  Medchemcomm       Date:  2019-06-20       Impact factor: 3.597

Review 4.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target.

Authors:  Alyssa C Fasciano; Lamyaa Shaban; Joan Mecsas
Journal:  EcoSal Plus       Date:  2019-02

5.  Identification of Small Molecules Blocking the Pseudomonas aeruginosa type III Secretion System Protein PcrV.

Authors:  Charlotta Sundin; Michael Saleeb; Sara Spjut; Liena Qin; Mikael Elofsson
Journal:  Biomolecules       Date:  2021-01-04

Review 6.  Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.

Authors:  Julia A Hotinger; Heather A Pendergrass; Aaron E May
Journal:  Biomolecules       Date:  2021-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.